Insights into dasatinib use and outcomes in real-world patients with chronic myeloid leukemia

Haematologica. 2023 Aug 1;108(8):2224-2228. doi: 10.3324/haematol.2022.282237.

Authors

Josephine A Adattini¹, Annette S Gross², Nicole Wong Doo³, Andrew J McLachlan⁴

Affiliations

¹ Sydney Pharmacy School, The University of Sydney, Sydney, NSW.
² Sydney Pharmacy School, The University of Sydney, Sydney, NSW, Australia; Clinical Pharmacology Modelling and Simulation, GlaxoSmithKline RD, Sydney, NSW.
³ Concord Cancer Centre, Concord Repatriation General Hospital, Sydney, NSW.
⁴ Sydney Pharmacy School, The University of Sydney, Sydney, NSW. andrew.mclachlan@sydney.edu.au.

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Antineoplastic Agents* / adverse effects
Dasatinib / adverse effects
Humans
Imatinib Mesylate / therapeutic use
Leukemia, Myelogenous, Chronic, BCR-ABL Positive* / drug therapy
Leukemia, Myeloid, Chronic-Phase* / drug therapy
Protein Kinase Inhibitors / adverse effects

Substances

Dasatinib
Imatinib Mesylate
Protein Kinase Inhibitors
Antineoplastic Agents

Grants and funding

Funding: This work was supported by the Peter Coates Postgraduate Scholarship in Ethnopharmacology provided by GlaxoSmithKline.